Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Cystic fibrosis Stories

Cystic Fibrosis Flare-ups May Be Caused By Buttery Molecule Diacetyl
2014-02-24 06:52:58

By Michael Price, San Diego State University Katrine Whiteson and colleagues identified a lung-damaging molecule in higher concentrations in cystic fibrosis patients during symptom flare-ups. A molecule previously linked to lung injuries in factory workers producing microwave popcorn might play an important role in microbial infections of the lung suffered by people with cystic fibrosis (CF), according to a recent study led by San Diego State University postdoctoral researcher Katrine...

2014-02-19 08:31:18

SAN DIEGO, Feb. 19, 2014 /PRNewswire/ -- CURx Pharmaceuticals today announced it has entered into a global license agreement with Gilead Sciences, Inc. for development of Fosfomycin:Tobramycin for Inhalation (FTI) to treat Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients. FTI is ready for Phase III clinical trials, having successfully completed a Phase II trial in CF patients. (Logo: http://photos.prnewswire.com/prnh/20140212/MM64137LOGO) "This is a great...

2014-02-18 04:20:49

ALBANY, New York, February 18, 2014 /PRNewswire/ -- MarketResearchReports.Biz includes new market research report " Cystic Fibrosis Therapeutics In Major Developed Markets To 2019 - CFTR Modulators Initiate Drive Towards Personalized Treatment And Market Growth" to its large collection of research reports....

2014-02-10 16:26:36

Successes in cystic fibrosis care delivery and drug development serve as a model for policymakers and greater rare disease community BETHESDA, Md., Feb. 10, 2014 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation will host a briefing on Capitol Hill to highlight how care delivery and drug development models in cystic fibrosis are an example for health policy experts seeking new ways to treat rare diseases and accelerate drug development. The panel discussion, "Personalized Medicine...

2014-02-10 08:27:53

Study Aims To Evaluate Improvement in Lung Function after Treatment with NOxCureCF REHOVOT, Israel, February 10, 2014 /PRNewswire/ -- Advanced Inhalation Therapies (AIT Ltd.), a drug development company, announced today it added Schneider Children's Medical Center of Israel as the second site in its multicenter, open-label, Phase II clinical trial of NOxCureCF, a respiratory treatment for patients with cystic fibrosis (CF). Schneider Children's is the largest children's...

2014-02-06 23:25:01

ResearchMoz.us include new market research report "Cystic Fibrosis Therapeutics in Major Developed Markets to 2019" to its huge collection of research reports. Full Report @ http://www.researchmoz.us/cystic-fibrosis-therapeutics-in-major-developed-markets-to-2019-cftr-modulators-initiate-drive-towards-personalized-treatment-and-market-growth-report.html Albany, NewYork (PRWEB) February 06, 2014 GBI Research has released its pharma report “Cystic Fibrosis Therapeutics in Major...

2014-01-25 23:03:29

AIReS’ offices and team members found many ways to give back during the holiday season. Pittsburgh, PA (PRWEB) January 25, 2014 AIReS encourages our employees to give back to the community, through company-sponsored initiatives, office benefit drives, and individual volunteer opportunities. Each holiday season, our dedicated staff members continue to inspire us in the ways they give back. Here are some highlights: Each year our company supports several charities. This year, donations on...

2014-01-23 08:30:37

REHOVOT, Israel, January 23, 2014 /PRNewswire/ -- Advanced Inhalation Therapies (AIT), a leader in the development of nitric oxide (NO) therapeutics for the treatment of infectious respiratory diseases, announced today that its lead investigator will present clincial trial results at the upcoming 2014 American Thoracic Society (ATS) International Conference Committee in San Diego, California, May16 to 21, 2014. The presentation entitled "Prospective, double-blind,...

2014-01-14 23:21:24

Grant to Fulfill Wishes for Children Living with Cystic Fibrosis Narberth, PA (PRWEB) January 14, 2014 The Take a Breather Foundation is proud to announce that they have been awarded a $25,000 grant from the Julianna Hike Fund-Endowed of The Philadelphia Foundation. This grant will help the Take A Breather Foundation further it's mission of fulfilling wishes for children living with cystic fibrosis (CF). The Julianna Hike Fund focuses its support on organizations assisting children or...

2014-01-08 12:30:46

ATLANTA, Jan. 8, 2014 /PRNewswire/ -- The Celtaxsys Board of Directors today announced that Greg Duncan has been appointed as President and Chief Executive Officer (CEO) and will join the board of directors effective immediately. Mr. Duncan joins Celtaxsys following his most recent role as an Executive Committee member and President of North America for Brussels based UCB, prior to which he served as a Senior Vice-President at Pfizer where his duties included leading US marketing, as...


Latest Cystic fibrosis Reference Libraries

Cystic Fibrosis
2013-07-19 15:03:45

Cystic fibrosis, also called mucoviscidosis, is an autosomal recessive genetic disorder of the viscous secretions in the body. In turn, it effects the lungs, pancreas, liver, and intestines, as well as all other exocrine glands in the body. The most common genetic mutation that causes CF is a deletion of three nucleotides that results in a loss of phenylalanine, an amino acid at the 508th position on the protein. It should be noted, however, that there are over a thousand other mutations that...

More Articles (1 articles) »